Transcriptional regulation in the mouse atrioventricular conduction system

Angela V. Edwards, Dorene L. Davis, Amy L. Juraszek, Andy Wessels, John B E Burch, Markwald

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We identified a GATA6 gene enhancer that selectively marks the developing atrioventricular conduction system (AVCS) in transgenic mice. This enhancer reads anterior/posterior and medial/lateral positional information early in the cardiogenic programme and remains active in progressively more restricted subsets of heart cells leading up to AVCS formation. Additional experiments will be required to determine if the potential to be recruited into the AVCS is similarly restricted to a subset of myocardial cells early in the cardiogenic programme or if this enhancer can also be activated de novo in cells that initially reside outside this field. We are using several strategies to identify factors that regulate this and other AVCS enhancers and hence govern AVCS function. We are also using this enhancer to make transgenic mice that express Cre, or an inducible form of Cre, to track lineages and to delete floxed genes in the developing or mature AVCS. This Cre/lox approach provides a means to deconstruct complex congenital heart phenotypes that involve the conduction system and to test whether genes are required to form the AVCS or to maintain AVCS function. Lastly, we are exploring strategies to isolate and analyse AVCS cells from normal and affected hearts.

Original languageEnglish (US)
Pages (from-to)177-193
Number of pages17
JournalNovartis Foundation Symposium
Volume250
StatePublished - 2003

Fingerprint

Transgenic Mice
Genes
Phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Edwards, A. V., Davis, D. L., Juraszek, A. L., Wessels, A., Burch, J. B. E., & Markwald (2003). Transcriptional regulation in the mouse atrioventricular conduction system. Novartis Foundation Symposium, 250, 177-193.

Transcriptional regulation in the mouse atrioventricular conduction system. / Edwards, Angela V.; Davis, Dorene L.; Juraszek, Amy L.; Wessels, Andy; Burch, John B E; Markwald.

In: Novartis Foundation Symposium, Vol. 250, 2003, p. 177-193.

Research output: Contribution to journalArticle

Edwards, AV, Davis, DL, Juraszek, AL, Wessels, A, Burch, JBE & Markwald 2003, 'Transcriptional regulation in the mouse atrioventricular conduction system', Novartis Foundation Symposium, vol. 250, pp. 177-193.
Edwards, Angela V. ; Davis, Dorene L. ; Juraszek, Amy L. ; Wessels, Andy ; Burch, John B E ; Markwald. / Transcriptional regulation in the mouse atrioventricular conduction system. In: Novartis Foundation Symposium. 2003 ; Vol. 250. pp. 177-193.
@article{5c7ea5ac95fe43758021d8498d035f08,
title = "Transcriptional regulation in the mouse atrioventricular conduction system",
abstract = "We identified a GATA6 gene enhancer that selectively marks the developing atrioventricular conduction system (AVCS) in transgenic mice. This enhancer reads anterior/posterior and medial/lateral positional information early in the cardiogenic programme and remains active in progressively more restricted subsets of heart cells leading up to AVCS formation. Additional experiments will be required to determine if the potential to be recruited into the AVCS is similarly restricted to a subset of myocardial cells early in the cardiogenic programme or if this enhancer can also be activated de novo in cells that initially reside outside this field. We are using several strategies to identify factors that regulate this and other AVCS enhancers and hence govern AVCS function. We are also using this enhancer to make transgenic mice that express Cre, or an inducible form of Cre, to track lineages and to delete floxed genes in the developing or mature AVCS. This Cre/lox approach provides a means to deconstruct complex congenital heart phenotypes that involve the conduction system and to test whether genes are required to form the AVCS or to maintain AVCS function. Lastly, we are exploring strategies to isolate and analyse AVCS cells from normal and affected hearts.",
author = "Edwards, {Angela V.} and Davis, {Dorene L.} and Juraszek, {Amy L.} and Andy Wessels and Burch, {John B E} and Markwald",
year = "2003",
language = "English (US)",
volume = "250",
pages = "177--193",
journal = "Novartis Foundation Symposium",
issn = "1528-2511",
publisher = "Novartis Foundation",

}

TY - JOUR

T1 - Transcriptional regulation in the mouse atrioventricular conduction system

AU - Edwards, Angela V.

AU - Davis, Dorene L.

AU - Juraszek, Amy L.

AU - Wessels, Andy

AU - Burch, John B E

AU - Markwald,

PY - 2003

Y1 - 2003

N2 - We identified a GATA6 gene enhancer that selectively marks the developing atrioventricular conduction system (AVCS) in transgenic mice. This enhancer reads anterior/posterior and medial/lateral positional information early in the cardiogenic programme and remains active in progressively more restricted subsets of heart cells leading up to AVCS formation. Additional experiments will be required to determine if the potential to be recruited into the AVCS is similarly restricted to a subset of myocardial cells early in the cardiogenic programme or if this enhancer can also be activated de novo in cells that initially reside outside this field. We are using several strategies to identify factors that regulate this and other AVCS enhancers and hence govern AVCS function. We are also using this enhancer to make transgenic mice that express Cre, or an inducible form of Cre, to track lineages and to delete floxed genes in the developing or mature AVCS. This Cre/lox approach provides a means to deconstruct complex congenital heart phenotypes that involve the conduction system and to test whether genes are required to form the AVCS or to maintain AVCS function. Lastly, we are exploring strategies to isolate and analyse AVCS cells from normal and affected hearts.

AB - We identified a GATA6 gene enhancer that selectively marks the developing atrioventricular conduction system (AVCS) in transgenic mice. This enhancer reads anterior/posterior and medial/lateral positional information early in the cardiogenic programme and remains active in progressively more restricted subsets of heart cells leading up to AVCS formation. Additional experiments will be required to determine if the potential to be recruited into the AVCS is similarly restricted to a subset of myocardial cells early in the cardiogenic programme or if this enhancer can also be activated de novo in cells that initially reside outside this field. We are using several strategies to identify factors that regulate this and other AVCS enhancers and hence govern AVCS function. We are also using this enhancer to make transgenic mice that express Cre, or an inducible form of Cre, to track lineages and to delete floxed genes in the developing or mature AVCS. This Cre/lox approach provides a means to deconstruct complex congenital heart phenotypes that involve the conduction system and to test whether genes are required to form the AVCS or to maintain AVCS function. Lastly, we are exploring strategies to isolate and analyse AVCS cells from normal and affected hearts.

UR - http://www.scopus.com/inward/record.url?scp=2142857215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142857215&partnerID=8YFLogxK

M3 - Article

C2 - 12956330

AN - SCOPUS:2142857215

VL - 250

SP - 177

EP - 193

JO - Novartis Foundation Symposium

JF - Novartis Foundation Symposium

SN - 1528-2511

ER -